Bajaj Finance Raises About Rs 11,700 Crore Through a QIP
Bajaj Finance sold 114,146,341 shares at Rs 1,025 each to qualified institutional buyers.
Key Takeaways
- Bajaj Finance raised about Rs 11,700 crore through a QIP.
- It allocated 114,146,341 shares at Rs 1,025 each, about 3.3% above the Rs 992.25 floor price.
- The issue closed on November 16, 2026, and the shares were allotted on November 17.
- Bajaj Finance said it will use the money mainly to repay borrowings.
Table of Contents 6 sections
Bajaj Finance has closed its qualified institutions placement (QIP), raising about Rs 11,700 crore from large institutional investors. A committee of the company's board declared the issue closed on November 16, 2026, and set the issue price at Rs 1,025 per share.
Bajaj Finance allocated 114,146,341 equity shares of face value Re 1 each at that price, which includes a premium of Rs 1,024 per share. The issue price is about 3.3% above the floor price of Rs 992.25 per share.
Bajaj Finance QIP at a glance
| Detail | Value |
|---|---|
| Company | Bajaj Finance |
| Type of issue | Qualified institutions placement (QIP) |
| Amount raised | About Rs 11,700 crore |
| Shares allocated | 114,146,341 equity shares of Re 1 each |
| Issue price | Rs 1,025 per share, including a premium of Rs 1,024 |
| Floor price | Rs 992.25 per share |
| Issue price over floor | About 3.3% |
| Issue closed | November 16, 2026 |
| Shares allotted | November 17, 2026 |
| Allotted to | Qualified institutional buyers |
Bajaj Finance QIP allotment
The company's allotment committee met on November 17, 2026 to allot the shares.
Bajaj Finance's QIP is part of a Rs 17,500 crore fundraise
The QIP is one part of a larger fundraise. In early October 2026, Bajaj Finance's board approved raising up to Rs 17,500 crore: up to Rs 11,700 crore through a QIP and up to Rs 5,800 crore through warrants issued to its promoter, Bajaj Finserv. The company had said it could offer the QIP at a discount of up to 5% to the floor price, but the final price came in above the floor.
| When | What happened |
|---|---|
| Early October 2026 | Board approves a fundraise of up to Rs 17,500 crore through a QIP and warrants to Bajaj Finserv |
| November 10, 2026 | Bajaj Finance allots about 5.74 crore warrants to Bajaj Finserv at Rs 1,010 each |
| November 11, 2026 | QIP opens with a floor price of Rs 992.25 per share |
| November 16, 2026 | QIP closes and shares are allocated at Rs 1,025 each |
| November 17, 2026 | 114,146,341 shares are allotted to the investors |
Bajaj Finance says the QIP money will go toward repaying borrowings
Bajaj Finance said it will use the money raised mainly to repay its borrowings. The company's QIP committee also approved the placement document dated November 16, 2026.
Where Bajaj Finance stands after the QIP
Bajaj Finance has raised about Rs 11,700 crore through the QIP, by selling 114,146,341 shares at Rs 1,025 each. The QIP is the larger part of the fundraise of up to Rs 17,500 crore that its board approved in October 2026, alongside warrants issued to Bajaj Finserv.
More news
Frequently Asked Questions
How much did Bajaj Finance raise through its QIP?
What is the Bajaj Finance QIP?
How many shares did Bajaj Finance issue in the QIP?
What was the issue price of the Bajaj Finance QIP?
What was the floor price of the Bajaj Finance QIP?
How far above the floor price was the Bajaj Finance issue price?
When did the Bajaj Finance QIP close?
When did the Bajaj Finance QIP open?
Who could buy shares in the Bajaj Finance QIP?
How many shares in total did Bajaj Finance allot in the QIP?
How will Bajaj Finance use the QIP money?
Is the QIP part of a larger Bajaj Finance fundraise?
More in Business
SML Mahindra Sets Rs 3,506 Price for Rs 1,450 Crore Rights Issue
SML Mahindra will sell rights shares at Rs 3,506 each in a rights issue of up to Rs 1,450 crore.
Mahindra Last Mile Mobility and Uber Plan 5,000 Electric Autos
Mahindra Last Mile Mobility and Uber plan 5,000 electric autos on Uber over the next 12 months.
Biocon Gets US FDA Nod for Breast Cancer Biosimilar Pebrilzo
Biocon has received US FDA approval for Pebrilzo, its biosimilar of the breast cancer drug Perjeta.
